Literature DB >> 9647672

Contribution of basic residues of the D and H helices in heparin binding to protein C inhibitor.

L L Neese1, C A Wolfe, F C Church.   

Abstract

Protein C inhibitor (PCI) is a heparin-binding serine protease inhibitor (serpin) that regulates hemostatic proteases such as activated protein C (APC) and thrombin. The work described here provides further evidence that the PCI H helix, but not the D helix, has a major role in heparin-accelerated inhibition of APC and thrombin. We previously identified Arg-269 and Lys-270 of the H helix [R269A/K270A "H1" recombinant PCI (rPCI)] as important residues both for heparin-accelerated inhibition of thrombin and APC and for heparin-Sepharose binding (Shirk, R. A., Elisen, M. G. L. M., Meijers, J. C. M., and Church, F. C. (1994) J. Biol. Chem. 269, 28690-28695). H1 rPCI was used as a template for Ala-scanning mutagenesis of other H helix basic residues (H1-K266A, H1-K273A, and H1-K266A/K273A) and of the D helix basic residues (H1-K82A, H1-K86A, H1-R90A, and H1-K82A/K86A/R90A). Compared to wild-type rPCI/heparin (k2 = 2.2 x 10(7) M-1 min-1 for thrombin), heparin-accelerated thrombin inhibition was decreased 2.4-fold by H1 rPCI, 4.4-fold by H1-K266A rPCI, and 8-fold by H1-K273A rPCI. H1-K266A/K273A rPCI thrombin inhibition was essentially not accelerated by heparin. A similar trend was found for APC-heparin inhibition using these H helix rPCI mutants. In contrast, the D helix rPCI mutants did not have further reduced heparin-stimulated thrombin or APC inhibition compared to H1 rPCI. Interestingly, all of the H and D helix rPCI mutants had reduced heparin-Sepharose binding activity (ranging from 180 to 360 mM NaCl) compared to wild-type rPCI and H1 rPCI, which eluted at 650 and 430 mM NaCl, respectively. These data suggest that all four basic residues (Lys-266, Arg-269, Lys-270, Lys-273) in the H helix of PCI form a heparin binding site. Our results also imply that while the D helix basic residues (Lys-80, Lys-86, and Arg-90) contribute to overall heparin binding, they are not necessary for heparin-accelerated activity. We conclude that the primary heparin binding site of PCI is the H helix and not the D helix as found in other homologous heparin-binding serpins such as antithrombin III, heparin cofactor II, and protease nexin 1. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9647672     DOI: 10.1006/abbi.1998.0716

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

Review 1.  Trousseau's syndrome: multiple definitions and multiple mechanisms.

Authors:  Ajit Varki
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

2.  Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex.

Authors:  Wei Li; Ty E Adams; Jyoti Nangalia; Charles T Esmon; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

3.  Suggestions on leading an academic research laboratory group.

Authors:  Frank C Church
Journal:  Open Life Sci       Date:  2022-06-15       Impact factor: 1.311

4.  Basic Residues of β-Sheet A Contribute to Heparin Binding and Activation of Vaspin (Serpin A12).

Authors:  David Ulbricht; Kathrin Oertwig; Kristin Arnsburg; Anja Saalbach; Jan Pippel; Norbert Sträter; John T Heiker
Journal:  J Biol Chem       Date:  2016-12-09       Impact factor: 5.157

5.  Mutation of the H-helix in antithrombin decreases heparin stimulation of protease inhibition.

Authors:  Patrick R Gonzales; Timothy D Walston; Laureano O Camacho; Dana M Kielar; Frank C Church; Alireza R Rezaie; Scott T Cooper
Journal:  Biochim Biophys Acta       Date:  2007-08-30

6.  Heparin activation of protein Z-dependent protease inhibitor (ZPI) allosterically blocks protein Z activation through an extended heparin-binding site.

Authors:  Xin Huang; Richard Swanson; Steven T Olson
Journal:  J Biol Chem       Date:  2022-05-10       Impact factor: 5.486

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.